Eisai and Biogen present promising lecanemab study results
Phase 3 research shows that Alzheimer’s disease treatment meets primary and secondary endpoints
Read More
Tag: lecanemab
Eisai’s Lecanemab phase 3 study meets primary endpoint
Results show reduction of clinical decline in global study of people with Alzheimer’s Disease
Read More
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
